Samsung Biologics announced on June 15 that it will participate in the 2026 BIO International Convention, the world's largest biotech and pharmaceutical expo.
The company is expanding its customer engagement by attending various global conferences this year. In March, it met with key clients during DCAT Week, followed by meetings at the American Association for Cancer Research (AACR) in April.
The BIO International Convention, organized by the Biotechnology Innovation Organization (BIO), is held annually in June and serves as a major platform for industry professionals to discuss partnerships.
This year's event will take place from June 22 to 25 at the San Diego Convention Center in California, with the theme "Innovation Driven by Purpose." More than 20,000 industry participants are expected to attend.
Since its founding in 2011, Samsung Biologics has been the only domestic company to participate with a standalone booth for 14 consecutive years. This year, it will set up a 140-square-meter booth in a prime location to enhance its order acquisition efforts.
The booth will feature a large LED wall and interactive touch screens to showcase its integrated services based on Contract Research, Development, and Manufacturing Organization (CRDMO) capabilities. The company plans to highlight its production capabilities, including its Rockville campus, to emphasize its competitiveness in global Contract Development and Manufacturing Organization (CDMO) services.
During the event, Samsung Biologics will also expand customer engagement through session presentations and on-site meetings. On the second day of the convention, June 23, James Choi, Vice President of Sales Support, will participate as a panelist in an official session titled "The Rise of Korea: Spotlight on Asia's New Innovation Hub." Jeff Mason, Senior Vice President of Americas Sales, will also present the company's global production capabilities during a live discussion.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.